Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

San Diego, California Clinical Trials

A listing of San Diego, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (14) clinical trials

Selpercatinib for the Treatment of Advanced Solid Tumors Lymphomas or Histiocytic Disorders With Activating RET Gene Alterations a Pediatric MATCH Treatment Trial

PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selpercatinib (LOXO-292) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in the RET pathway. SECONDARY OBJECTIVES: I. To estimate …

Phase

1.03 miles

Learn More »

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

This is a randomized double-blind, placebo-controlled, parallel-group study of pepinemab in early AD dementia defined as MCI and mild Alzheimer's dementia. The study is 40 weeks in duration, including a safety and efficacy evaluation 4 weeks after the last dose of study drug. Subjects with resolved adverse events at Week …

Phase

2.38 miles

Learn More »

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.

Phase

2.38 miles

Learn More »

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults 65 Years of Age

Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately

Phase

2.38 miles

Learn More »

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

This is a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study comprising approximately 4,060 subjects aged 18 years or above randomized in a 3:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo will be administered as a single intramuscular immunization. …

Phase

4.2 miles

Learn More »

Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

Phase

6.51 miles

Learn More »

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma. In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone. Subjects will be evaluated in 3 arms: Arm …

Phase

6.74 miles

Learn More »

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

Phase

7.86 miles

Learn More »

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

This study is a phase IIb, multicenter, multi-national, double-blind, randomized, parallel-arm, placebo-controlled study to evaluate the effect of 5 dose levels of CSJ117 (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard of care asthma therapy in adult subjects with inadequately controlled …

Phase

7.94 miles

Learn More »

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

This is a Phase 1b, open-label, adaptive design dose-ranging study to evaluate ADPKD biomarkers, PK, safety, tolerability, and pharmacodynamics (PD) of RGLS4326 administered via SC injection to patients with ADPKD. The goal is to assess the dose response relationship between RGLS4326 and ADPKD biomarkers. The study will consist of three …

Phase

9.44 miles

Learn More »